Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced a significant advancement in its sensor technology by its team of experts.
This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws. This advancement signals Inspira’s potential entry into the disposables market.
The development of the first HYLA™ variant, key to this advancement, marks a significant step towards its submission under a 510(k) pathway with the U.S. Food & Drug Administration (“FDA”), which is expected in the second half of 2024. This sensor technology is designed to be integrated with the Company’s INSPIRA ART100 and was submitted to the FDA in September 2023, with clearance anticipated in the first half of 2024.
The HYLA™ Blood Sensor line (the “Blood Sensor”) is set to transform intensive care unit (ICU) operations, offering continuous, real-time blood data collection and analysis. This enhances patient care with critical insights and alerts, with the aim to improve medical procedures and device efficiency.
Key features of the Blood Sensor include:
- High Accuracy: Achieves 95% accuracy relative to standard blood gas analyzers;
- Non-invasive: Eliminates the need for blood draws;
- Durability: Built to handle ICU and operating room environments;
- Versatility: Compatible with various medical procedures, including: the cardio pulmonary bypass, extracorporeal membrane oxygenation, continuous renal replacement therapy, and dialysis; and
- Modular Design: Engineered to complement existing medical devices, targeting the two-million annual open-heart surgery patients globally.
In developing the HYLA™ Blood Sensor line, Inspira utilizes in-house lab testing as well as hospital collaborations for the purpose of clinical research and development. This approach has enabled to define the Blood Sensor’s disposable materials and methods, with HYLA’s planned razor blade business model. While primarily designed for INSPIRA ART devices, plans are underway also to offer a variant of the Blood Sensor as a standalone device.
Dagi Ben-Noon, CEO of Inspira Technologies, commented: “With our sensor technology, we are not only enriching our INSPIRA ART device line but also forging a path into the disposables market, setting the stage for groundbreaking developments in healthcare.”